Skinny-Label Lives to See Another Day
FDA Law Blog
OCTOBER 16, 2024
There, as we explained back in July , Novartis argued that FDA’s approval of a generic ENTRESTO with indication information modified rather than simply omitted “represents a sharp departure from FDA’s statutory and regulatory mandate to require that a generic drug be the ‘same’ as its reference listed drug.”
Let's personalize your content